4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 4, 2007, Pages 1586-1605

  Matulenko, Mark A ^a   Paight, Ernest S ^a   Frey, Robin R ^a   Gomtsyan, Arthur ^a   DiDomenico Jr , Stanley ^a   Jiang, Meiqun ^a   Lee, Chih Hung ^a   Stewart, Andrew O ^a   Yu, Haixia ^a   Kohlhaas, Kathy L ^a   Alexander, Karen M ^a   McGaraughty, Steve ^a   Mikusa, Joseph ^a   Marsh, Kennan C ^a   Muchmore, Steven W ^a   Jakob, Clarissa L ^a   Kowaluk, Elizabeth A ^a   Jarvis, Michael F ^a   Bhagwat, Shripad S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Acetylene; Adenosine kinase; Analgesic; Inhibitor

Indexed keywords

5 (3 BROMOPHENYL) 7 (6 MORPHOLIN 4 YLPYRIDIN 3 YL)PYRIDO[2,3 D]PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (2 MORPHOLIN 4 YLPYRIMIDIN 5 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (4 DIMETHYLAMINOPHENYLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (4 MORPHOLIN 4 YLPHENYLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (5 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (6 DIMETHYLAMINOPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 (6 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 (4 CHLOROPHENYL) 6 [6 [(2 METHOXYETHYL)METHYLAMINO]PYRIDIN 3 YLETHYNYL]PYRIMIDIN 4 YLAMINE; 5 (4 DIMETHYLAMINOPHENYL) 6 (6 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 BENZO[1,3]DIOXOL 5 YL 6 (6 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 BENZO[B]THIOPHEN 2 YL 6 (6 MORPHOLIN 4 YLPYRIDINE 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 5 BENZOFURAN 2 YL 6 (6 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL)PYRIMIDIN 4 YLAMINE; 6 (6 MORPHOLIN 4 YLPYRIDIN 3 YLETHYNYL) 5 THIOPHEN 2 YLPYRIMIDIN 4 YLAMINE; ABT 702; FORMALDEHYDE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DETERMINATION; DRUG POTENCY; MALE; NOCICEPTIVE STIMULATION; NONHUMAN; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADENOSINE KINASE; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; INHIBITORY CONCENTRATION 50; MICE; MORPHOLINES; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847771147     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.12.029     Document Type: Article

References (69)

1. Millan M.J. Prog. Neurobiol. 57 (1999) 1-164
2. Williams M., and Burnstock G. In: Jacobson K.A., and Jarvis M.F. (Eds). Purinergic Approaches in Experimental Therapeutics (1997), Wiley-liss, New York 3-26
3. Ralevic V., and Burnstock G. Pharmacol. Rev. 50 (1998) 413-492
4. Jarvis M.F. Rev. Analgesia 7 (2003) 1-23
5. Williams M., and Jarvis M.F. Biochem. Pharmacol. 59 (2000) 1173-1185
6. Yan L., Burbiel J.C., Maaß A., and Müller C.E. Expert Opin. Emerging Drugs 8 (2003) 537-576
7. See the supplemental section for a list of key references.
8. McGaraughty S., Cowart M.D., Jarvis M.F., and Berman R.F. Curr. Top. Med. Chem. 5 (2005) 43-58
9. McGaraughty S., Cowart M., and Jarvis M.F. CNS Drug Rev. 7 (2001) 415-432
10. Kowaluk E.A., and Jarvis M.F. Expert Opin. Investig. Drugs 9 (2000) 555-564
11. Millan M.J. Prog. Neurobiol. 66 (2002) 355-474
12. Keil II G.J., and DeLander G.E. Eur. J. Pharmacol. 271 (1994) 37-46
13. Keil II G.J., and DeLander G.E. Life Sci. 51 (1992) PL171-PL176
14. Firestein G.S. Drug Dev. Res. 39 (1996) 371-376
15. Rosengren S., Bong G.W., and Firestein G.S. J. Immunol. 154 (1995) 5444-5451
16. Gomtsyan A., Didomenico S., Lee C.-H., Stewart A.O., Bhagwat S.S., Kowaluk E.A., and Jarvis M.F. Bioorg. Med. Chem. Lett. 14 (2004) 4165-4168
17. Zheng G.Z., Mao Y., Lee C.-H., Pratt J.K., Koenig J.R., Perner R.J., Cowart M.D., Gfesser G.A., McGaraughty S., Chu K.L., Zhu C., Yu H., Kohlhaas K., Alexander K.M., Wismer C.T., Mikusa J., Jarvis M.F., Kowaluk E.A., and Stewart A.O. Bioorg. Med. Chem. Lett. 13 (2003) 3041-3044
18. Perner R.J., Gu Y.-G., Lee C.-H., Bayburt E.K., McKie J., Alexander K.M., Kohlhaas K.L., Wismer C.T., Mikusa J., Jarvis M.F., Kowaluk E.A., and Bhagwat S.S. J. Med. Chem. 46 (2003) 5249-5257
19. Gfesser G.A., Bayburt E.K., Cowart M., DiDomenico S., Gomtsyan A., Lee C.-H., Stewart A.O., Jarvis M.F., Kowaluk E.A., and Bhagwat S.S. Eur. J. Med. Chem. 38 (2003) 245-252
20. Cowart M., Lee C.-H., Gfesser G.A., Bayburt E.K., Bhagwat S.S., Stewart A.O., Yu H., Kohlhaas K., McGaraughty S., Wismer C.T., Mikusa J., Zhu C.Z., Alexander K.M., Jarvis M.F., and Kowaluk E.A. Bioorg. Med. Chem. Lett. 11 (2001) 83-86
21. Zheng G.Z., Lee C.H., Pratt J.K., Perner R.J., Jiang M.Q., Gomtsyan A., Matulenko M.A., Mao Y., Koenig J.R., Kim K.H., Muchmore S., Yu H., Kohlhaas K., Alexander K.M., McGaraughty S., Chu K.L., Wismer C.T., Mikusa J., Jarvis M.F., Marsh K., Kowaluk E.A., Bhagwat S.S., and Stewart A.O. Bioorg. Med. Chem. Lett. 11 (2001) 2071-2074
22. Lee C.-H., Jiang M., Cowart M., Gfesser G., Perner R., Kim K.H., Gu Y.G., Williams M., Jarvis M.F., Kowaluk E.A., Stewart A.O., and Bhagwat S.S. J. Med. Chem. 44 (2001) 2133-2138
23. Matulenko M.A., Lee C.-H., Jiang M., Frey R.R., Cowart M.D., Bayburt E.K., DiDomenico Jr. S., Gfesser G.A., Gomtsyan A., Zheng G.Z., McKie J.A., Stewart A.O., Yu H., Kohlhaas K.L., Alexander K.M., McGaraughty S., Wismer C.T., Mikusa J., Marsh K.C., Snyder R.D., Diehl M.S., Kowaluk E.A., Jarvis M.F., and Bhagwat S.S. Bioorg. Med. Chem. 13 (2005) 3705-3720
24. Perner R.J., Lee C.-H., Jiang M., Gu Y.G., Didomenico S., Bayburt E.K., Alexander K.M., Kohlhaas K.L., Jarvis M.F., Kowaluk E.A., and Bhagwat S.S. Bioorg. Med. Chem. Lett. 15 (2005) 2803-2807
25. Gomtsyan A., and Lee C.-H. Curr. Pharm. Design 10 (2004) 1093-1103
26. Gomtsyan A., Didomenico S., Lee C.-H., Matulenko M.A., Kim K., Kowaluk E.A., Wismer C.T., Mikusa J., Yu H., Kohlhaas K., Jarvis M.F., and Bhagwat S.S. J. Med. Chem. 45 (2002) 3639-3648
27. Muchmore S.W., Smith R.A., Stewart A.O., Cowart M.D., Gomtsyan A., Matulenko M.A., Yu H., Severin J.M., Bhagwat S.S., Lee C.-H., Kowaluk E.A., Jarvis M.F., and Jakob C.L. J. Med. Chem. 49 (2006) 6726-6731
28. Budešínský Z., Roubínek F., and Svátek E. Collect. Czech. Chem. Commun. 30 (1965) 3730-3743
29. Sonogashira K. In: Trost B.M., and Fleming I. (Eds). Comprehensive Organic Synthesis Vol. 3 (1991), Pergamon, Oxford 521-549
30. Sonogashira K. J. Organomet. Chem. 653 (2002) 46-49
31. Tykwinski R.R. Angew. Chem., Int. Ed. 42 (2003) 1566-1568
32. Rossi R., Carpita A., and Bellina F. Org. Prep. Proceed. Int. 27 (1995) 127-160
33. Bumagin N.A. Russ. Chem. Bull. 45 (1996) 2031-2050
34. Izv. Akad. Nauk Ser. Khim. (1996) 2148-2167
35. Sonogashira K. In: Diederich F., and Stang P.J. (Eds). Metal-Catalyzed Cross-Coupling Reactions (1998), Wiley-VCH, Weinheim 203-229
36. These bis acetylene analogs were screened and found to be inactive as AK inhibitors.
37. Siemsen P., Livingston R.C., and Diederich F. Angew. Chem., Int. Ed. 39 (2000) 2632-2657
38. Soheili A., Albaneze-Walker J., Murry J.A., Dormer P.G., and Hughes D.L. Org. Lett. 5 (2003) 4191-4194
39. Ma Y., Song C., Jiang W., Wu Q., Wang Y.-G., Liu X., and Andrus M.B. Org. Lett. 5 (2003) 3317-3319
40. Urgaonkar S., and Verkade J.G. J. Org. Chem. 69 (2004) 5752-5755
41. Cheng J., Sun Y., Wang F., Guo M., Xu J.-H., Pan Y., and Zhang Z. J. Org. Chem. 69 (2004) 5428-5432
42. Shirakawa E., Kitabata T., Otsuka H., and Tsuchimoto T. Tetrahedron 61 (2005) 9878-9885
43. Zhang G. Synlett (2005) 619-622
44. Li J.-H., Zhang X.-D., and Xie Y.-X. Synthesis (2005) 804-808
45. Palladium scavengers were not attempted.
46. Jarvis M.F., Yu H., Kohlhaas K., Alexander K., Lee C.-H., Jiang M., Bhagwat S.S., Williams M., and Kowaluk E.A. J. Pharmacol. Exp. Ther. 295 (2000) 1156-1164
47. Kowaluk E.A., Kohlhaas K.L., Bannon A., Gunther K., Lynch III J.J., and Jarvis M.F. Pharmacol. Biochem. Behav. 63 (1999) 83-91
48. Kowaluk E.A., Mikusa J., Wismer C.T., Zhu C.Z., Schweitzer E., Lynch J.J., Lee C.-H., Jiang M., Bhagwat S.S., Gomtsyan A., McKie J., Cox B.F., Polakowski J., Reinhart G., Williams M., and Jarvis M.F. J. Pharmacol. Exp. Ther. 295 (2000) 1165-1174
49. Suzuki R., Stanfa L.C., Kowaluk E.A., Williams M., Jarvis M.F., and Dickenson A.H. Br. J. Pharmacol. 132 (2001) 1615-1623
50. Kim S.H., and Chung J.M. Pain 50 (1992) 355-363
51. Tsai C., Kumar S., Ma B., and Nussinov R. Protein Sci. 8 (1999) 1181-1190
52. Fischer E. Ber. Dtsch. Chem. Ges. 27 (1894) 2985-2993
53. Koshland Jr. D.E. Proc. Natl. Acad. Sci. U.S.A. 44 (1958) 98-105
54. Goh C.-S., Milburn D., and Gerstein M. Curr. Opin. Struct. Biol. 14 (2004) 104-109
55. James L.C., Roversi P., and Tawfik D.S. Science 299 (2003) 1362-1367
56. James L.C., and Tawfik D.S. Trends Biochem. Sci. 28 (2003) 361-368
57. Gutteridge A., and Thornton J. J. Mol. Biol. 346 (2005) 21-28
58. Bursavich M.G., and Rich D.H. J. Med. Chem. 45 (2002) 541-558
59. Specker E., Boettcher J., Brass S., Heine A., Lilie H., Schoop A., Mueller G., Griebenow N., and Klebe G. Chem. Med. Chem. 1 (2006) 106-117
60. cell) as well.
61. Leo, A. c log P, v 4.81 program available from Biobyte corp. Claremont, CA. Biobyte home page. http://biobyte.com. Purchased from Daylight.
62. % MPE = % maximal protective effect ([postdrug latency] - [vehicle latency])/([maximum latency] - [vehicle latency]) × 100%, where maximum (cutoff) latency was 180 s. Values represent means within ±8% and p < 0.05 to vehicle treated mice.
63. Boyle D.L., Kowaluk E.A., Jarvis M.F., Lee C.-H., Bhagwat S.S., Williams M., and Firestein G.S. J. Pharm. Exp. Ther. 296 (2001) 495-500
64. Schumacher M.A., Scott D.M., Mathews I.I., Ealick S.E., Roos D.S., Ullman B., and Brennan R.G. J. Mol. Biol. 296 (2000) 549-567
65. Initial attempts to synthesize a C(2)′ analog were unsuccessful. Studies were carried out on the C(5)′ and C(6)′ compounds only.
66. In previous studies (unreported), it was found the ABT-702 was metabolized primarily at the morpholine ring to give three components.
67. Mathews I.I., Erion M.D., and Earlick S.E. Biochemistry 37 (1998) 15607-15620
68. Serwinski P.R., and Lahti P.M. Org. Lett. 5 (2003) 2099-2102
69. Xu G., and Wang Y.-G. Org. Lett. 6 (2004) 985-987